Acadia Pharmaceuticals (ACAD) announced Daybue Stix is now broadly available in the United States for the treatment of Rett syndrome in adults and pediatric patients two years of age and older. The new formulation, approved by the U.S. Food and Drug Administration, FDA, in December 2025, is bioequivalent to the original DAYBUE oral solution, delivering the same efficacy and safety profile, while offering children and adults living with Rett syndrome new flexibility and choice regarding the dose volume and taste of their DAYBUE treatment.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- Arm upgraded, Mondelez downgraded: Wall Street’s top analyst calls
- Acadia Pharmaceuticals upgraded to Buy at BofA following 25% pullback
- Acadia Pharmaceuticals upgraded to Buy from Neutral at BofA
- Acadia Pharmaceuticals Appoints Jonathan Poole to Board, Audit Committee
- Acadia Pharmaceuticals price target raised to $34 from $31 at JPMorgan